Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Waxman’s Congressional Exclusivity Set To Expire, But There Will Be No Equivalents

Executive Summary

Retiring after 40 years in Congress, Waxman leaves an enormous legacy, but also many recent legislative defeats.

You may also be interested in...



FTC Competition Hearings: PhRMA, Former Rep. Waxman Advocate Focus On PBMs

FTC is assessing possible changes to competition and consumer protection enforcement law and policy, with a hearing on Innovation and IP Policy set for Oct. 23-24.

Sen. Hatch, Biopharma Industry Champion, Ready To Hang Up His Gloves

Hatch had a hand in major bipartisan legislation creating markets for generic drugs, orphan drugs, biosimilars, and dietary supplements.

Sen. Hatch, Biopharma Industry Champion, Ready To Hang Up His Gloves

Hatch had a hand in major bipartisan legislation creating markets for generic drugs, orphan drugs, biosimilars, and dietary supplements.

Related Content

Topics

UsernamePublicRestriction

Register

PS055895

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel